Document:

Exhibit
10.1

 

SIXTH
AMENDMENT TO MANAGEMENT SERVICES AGREEMENT

 

Reference
is made to the Management Services Agreement (as amended from time to time, the “Agreement”; capitalized terms used
but not defined herein have the meaning ascribed to them in the Agreement), dated as of May 12, 2018, by and between PAVmed Inc., a Delaware
corporation (“PAVmed”) and Lucid Diagnostics Inc., a Delaware corporation (“Lucid Diagnostics”).

 

WHEREAS,
as set forth in Section 3(b) of the Agreement, the parties have considered in good faith an adjustment to the Service Fee and hereby
wish to amend the Agreement to reflect such adjustment as set forth herein.

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth, and for other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the parties hereby agree as follows:

 

1.
Amendment. Effective July 1, 2022, Section 3(a) of the Agreement is hereby deleted in its entirety and replaced with the following:

 

“In
consideration of the Services, Lucid Diagnostics shall pay to PAVmed a fee of $550,000 per month, plus all reasonable, out-of-pocket
expenses incurred by PAVmed in connection with the performance of the Services (the “Service Fee”). The Service Fee
shall be payable on a monthly basis on the first day of the month following the month in which the Services in respect thereof have been
provided and shall be payable, at PAVmed’s election, in cash or shares of Lucid Diagnostics common stock (which shall be valued
at the volume weighted average price of such stock during the final ten trading days of the applicable month, but in no event shall such
shares be valued at a price per share lower than $0.70 (as may be equitably adjusted for stock dividends, subdivisions, combinations,
or other similar events affecting the Lucid Diagnostics common stock as a whole)), or a combination of the two. If PAVmed does not notify
Lucid Diagnostics of its election as to the form of payment of the Service Fee at least two (2) business days before the Service Fee
is due, PAVmed shall be deemed to have elected that the fee for such month be paid in shares of Lucid common stock. Notwithstanding the
foregoing, in no event shall Lucid Diagnostics issue any shares of its common stock to PAVmed in satisfaction of all or any portion of
any Service Fee if the issuance of such shares of common stock would exceed the maximum number of shares of common stock which Lucid
Diagnostics may issue hereunder without breaching Lucid Diagnostics’ obligations under the rules or regulations of The Nasdaq Stock
Market LLC (“Nasdaq”), unless Lucid Diagnostics obtains the approval of its stockholders as required by the applicable
rules of the Nasdaq for issuances of shares of its common stock hereunder in excess of such amount. If PAVmed elects for all or any portion
of the Service Fee to be paid in cash, Lucid Diagnostics may defer payment of all or any portion of the Service Fee payable in cash until
such time that it has sufficient cash to pay such amount, and in such case any unpaid Service Fee shall continue to accrue so long as
it remains unpaid.”

 

2.
Terms of Agreement. Except as expressly set forth in this amendment, the terms of the Agreement remain unchanged and in full force and
effect.

 

3.
Entire Agreement. This amendment, together with the Agreement, contains the entire understanding of the parties with respect to the subject
matter hereof and thereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters, which
the parties acknowledge have been merged into such documents, exhibits and schedules.

 

[remainder
of page left intentionally blank]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this agreement as of August 11, 2022.

 

AGREED
AND ACCEPTED BY:

 

	PAVMED INC.	 	LUCID DIAGNOSTICS INC.
	 	 	 	 	 
	By:	/s/ Lishan Aklog, M.D.	 	By:	/s/ Lishan Aklog, M.D.
	Name:	Lishan Aklog, MD	 	Name:	Lishan Aklog, MD
	Title:	Chairman and Chief Executive Officer	 	Title:	Chairman and Chief Executive OfficerExhibit
10.2

 

PAYROLL
AND BENEFIT EXPENSE REIMBURSEMENT agreement

 

This
Payroll and Benefit Expense Reimbursement Agreement, dated as of November 30, 2022 (this “Agreement”), is by and between
PAVmed Inc., a Delaware corporation (“PAVmed”), and Lucid Diagnostics Inc., a Delaware corporation (“Lucid
Diagnostics”).

 

WHEREAS,
Lucid Diagnostics is a subsidiary of PAVmed; and

 

WHEREAS,
PAVmed desires to pay for certain payroll and benefit-related expenses in respect Lucid Diagnostics personnel on behalf of Lucid Diagnostics,
and Lucid Diagnostics desires to reimburse PAVmed for the same.

 

NOW,
THEREFORE, the parties hereby agree as follows:

 

1.
Covered Expenses

 

(a)
General. Upon the terms and subject to the conditions contained herein, during the term of this Agreement, PAVmed has paid, and
will continue to pay, for certain payroll and benefit-related expenses (“Covered Expenses”) in respect of Lucid Diagnostics
personnel on behalf of Lucid Diagnostics, and Lucid Diagnostics desires to reimburse PAVmed for the same.

 

(b)
Records. PAVmed shall maintain appropriate and accurate books and records pertaining to the Covered Expenses it incurs in respect
hereof, and will make such books and records available to Lucid Diagnostics and its representatives at reasonable times and upon reasonable
notice.

 

2.
Term and Termination. The term of this Agreement shall commence on the date hereof and shall continue until such time as either
party gives the other party written notice of its election to terminate this Agreement.

 

3.
Reimbursement. Lucid Diagnostics shall reimburse PAVmed for all Covered Expenses paid by PAVmed in respect of Lucid Diagnostics
personnel on behalf of Lucid Diagnostics in accordance with the terms hereof. The Covered Expenses shall be reimbursed on a quarterly
basis or at such other frequency as the parties may determine, in cash or, subject to approval by the board of directors of each of PAVmed
and Lucid Diagnostics, shares of Lucid Diagnostics common stock (which shall be valued at the volume weighted average price of such stock
during the final ten trading days preceding the later of the two dates on which such stock issuance is approved by the board of directors
of each of PAVmed and Lucid Diagnostics, but in no event shall such shares be valued at a price per share lower than $0.40 (as may be
equitably adjusted for stock dividends, subdivisions, combinations, or other similar events affecting the Lucid Diagnostics common stock
as a whole)), or a combination of the two. If PAVmed does not notify Lucid Diagnostics of its election as to the form of payment of the
Covered Expenses at least sixty (60) days after the end of the quarter in respect of which such payment is due, PAVmed shall be deemed
to have elected that the fee for such month be paid in shares of Lucid Diagnostics common stock. Notwithstanding the foregoing, in no
event shall Lucid Diagnostics issue any shares of its common stock to PAVmed in satisfaction of all or any portion of any Covered Expenses
if the issuance of such shares of common stock would exceed the maximum number of shares of common stock which Lucid Diagnostics may
issue hereunder without breaching Lucid Diagnostics’ obligations under the rules or regulations of The Nasdaq Stock Market LLC
(“Nasdaq”), unless Lucid Diagnostics obtains the approval of its stockholders as required by the applicable rules of the
Nasdaq for issuances of shares of its common stock hereunder in excess of such amount. If PAVmed elects for all or any portion of the
Covered Expenses to be paid in cash, Lucid Diagnostics may defer payment of all or any portion of the Covered Expenses payable in cash
until such time that it has sufficient cash to pay such amount, and in such case any unpaid Covered Expenses shall continue to accrue
(without interest) so long as they remain unpaid.

 

    	 

     

    

 

4.
Tax Matters.

 

(a)
Lucid Diagnostics will be liable for and will reimburse PAVmed or pay, as applicable, any applicable sales or similar taxes with respect
to the Covered Expenses.

 

(b)
If Lucid Diagnostics is required to withhold from any amount owed to PAVmed for any taxes for which PAVmed is responsible, the amount
withheld shall be subtracted from the amount owed by Lucid Diagnostics and PAVmed will receive the amount remaining after the tax withheld.

 

5.
Limitation of Liability

 

(a)
General Limitation. PAVmed shall not be liable to Lucid Diagnostics or any other person for any act or omission or any alleged
act or omission in connection with its performance of (or failure to perform) its obligations under this Agreement, except where such
act or omission or alleged act or omission is finally judicially determined to have resulted from the gross negligence or willful misconduct
of PAVmed. In no event shall PAVmed have liability under or in respect of this Agreement in the aggregate in excess of the Covered Expenses
actually reimbursed by Lucid Diagnostics.

 

(b)
Force Majeure. PAVmed shall not be liable to Lucid Diagnostics or any other person for any act or omission or any alleged act
or omission in connection with its performance of (or failure to perform) its obligations under this Agreement from any cause beyond
its reasonable control, including without limitation acts of God, acts of civil or military authority, embargoes, epidemics, war, terrorist
acts, riots, insurrections, fires, explosions, earthquakes, nuclear accidents, floods, strikes, and power blackouts.

 

(c)
No Consequential Damages. Neither party shall have any liability to the other party hereunder for any consequential, exemplary,
incidental, indirect, prospective, punitive, remote or speculative damages.

 

(d)
Indemnification. Lucid Diagnostics shall indemnify, defend and hold harmless PAVmed, its affiliates, officers, directors, employees,
agents and representatives (collectively, the “Indemnified Persons”) from and against any and all losses, liabilities,
claims, damages, actions, fines, penalties, expenses or costs (including court costs and reasonable attorneys’ fees) suffered or
incurred by any such Indemnified Person relating to any claim of a third party arising from or in connection with PAVmed’s performance
of (or failure to perform) its obligations under this Agreement, except where such performance (or non-performance) is finally judicially
determined to have resulted from the gross negligence or willful misconduct of such Indemnified Person.

 

(e)
Survival. The parties hereto acknowledge and agree that the provisions of this Section 5 shall survive the termination of this
Agreement.

 

    	2

     

    

 

6.
Dispute Resolution

 

Any
dispute or controversy among the parties hereto arising out of or relating to this Agreement shall be finally settled by arbitration
in the City of New York, NY, administered by the American Arbitration Association. Judgment on the award may be enforced in any court
of competent jurisdiction. The parties expressly authorize the arbitrator to require that all or a portion of the prevailing party’s
fees and expenses in the arbitration be allocated to and borne by the other party, if the arbitrator determines that the other party’s
positions were sufficiently non-meritorious so as to make such allocation equitable.

 

7.
Miscellaneous

 

(a)
Entire Agreement. This Agreement sets forth the entire agreement of the parties with respect to the subject matter hereof, and
supersedes all other agreements, arrangements or understandings, written or oral, with respect to such subject matter.

 

(b)
Headings. Headings to Sections herein are for the convenience of the parties only, and are not intended to affect the meaning
or interpretation of this Agreement.

 

(c)
Amendments. This Agreement may not be amended except by a written instrument signed by both of the parties.

 

(d)
Assignment. Neither party may assign its rights or delegate its duties hereunder without the prior written consent of the other
party. This Agreement will be binding upon, and will inure to the benefit of, the successors and permitted assigns of the parties.

 

(e)
Relationship of the Parties. The parties are independent contractors, and are not partners or joint venturers, and nothing contained
herein is intended to create an agency relationship or a partnership or joint venture.

 

(f)
Employees. Employees or subcontractors of PAVmed shall not be considered employees of Lucid Diagnostics by reason of this Agreement.

 

(g)
Notices. All notices or other communications to be given hereunder to a party shall be in writing and shall be sent by delivery
in person, by nationally recognized courier service, by telecopy or by electronic mail. Any notice given hereunder shall be deemed to
have been given upon the earlier of: (i) receipt and (ii) two days after being sent by a nationally recognized courier service, return
receipt or proof of delivery requested.

 

    	3

     

    

 

(h)
Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware,
without regard to conflicts of law rules.

 

(i)
No Waiver. No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate
as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise
thereof or the exercise of any other right, power or remedy. No waiver of any provision of this Agreement shall be effective unless the
same shall be made in writing and signed by the party against whom such waiver is sought to be enforced.

 

(j)
Severability. If it is finally determined that any term or provision of this Agreement is invalid or unenforceable, the parties
agree that the court making the determination of invalidity or unenforceability shall reduce the scope, duration, or area of the term
or provision, delete specific words or phrases, or replace any invalid or unenforceable term or provision with a term or provision that
is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this
Agreement shall be enforceable as so modified.

 

(k)
No Third-Party Beneficiaries. Except for the right of PAVmed’s affiliates, officers, directors, employees, agents and representatives
to enforce their rights to indemnification under Section 5(d), this Agreement benefits solely the parties to this Agreement and their
respective permitted successors and assigns and nothing in this Agreement, express or implied, confers on any other person any legal
or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

 

(l)
Counterparts. This Agreement may be executed in two counterparts.

 

[Signature
page follows]

 

    	4

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

	 	PAVMED
    INC.
	 	 	 
	 	By:
    	/s/
    Lishan Aklog, M.D.
	 	Name:
    	Lishan
    Aklog, M.D.
	 	Title:
    	Chairman
    and Chief Executive Officer
	 	 	 
	 	LUCID
    DIAGNOSTICS INC.
	 	 	 
	 	By:
    	/s/
    Lishan Aklog, M.D.
	 	Name:
    	Lishan
    Aklog, M.D.
	 	Title:
    	Chairman
    and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]